BioMarin Pharmaceutical Inc. (FRA:BM8)
47.62
0.00 (0.00%)
At close: Nov 28, 2025
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $776.13M USD in the quarter ending September 30, 2025, with 4.08% growth. This brings the company's revenue in the last twelve months to $3.09B, up 12.39% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$3.09B
Revenue Growth
+12.39%
P/S Ratio
3.45
Revenue / Employee
$1.02M
Employees
3,040
Market Cap
9.09B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
| Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
| Dec 31, 2019 | 1.70B | 212.84M | 14.27% |
| Dec 31, 2018 | 1.49B | 177.57M | 13.52% |
| Dec 31, 2017 | 1.31B | 196.79M | 17.62% |
| Dec 31, 2016 | 1.12B | 226.96M | 25.50% |
| Dec 31, 2015 | 889.90M | 140.61M | 18.77% |
| Dec 31, 2014 | 749.28M | 200.80M | 36.61% |
| Dec 31, 2013 | 548.49M | 47.76M | 9.54% |
| Dec 31, 2012 | 500.72M | 59.37M | 13.45% |
| Dec 31, 2011 | 441.36M | 65.09M | 17.30% |
| Dec 31, 2010 | 376.27M | 51.61M | 15.90% |
| Dec 31, 2009 | 324.66M | 28.16M | 9.50% |
| Dec 31, 2008 | 296.49M | 174.91M | 143.86% |
| Dec 31, 2007 | 121.58M | 37.37M | 44.38% |
| Dec 31, 2006 | 84.21M | 58.54M | 228.06% |
| Dec 31, 2005 | 25.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
BioMarin Pharmaceutical News
- 13 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 20 days ago - BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England - PRNewsWire
- 21 days ago - BMRN February 2026 Options Begin Trading - Nasdaq
- 25 days ago - BioMarin Pharmaceutical (BMRN) Downgraded by Stifel: Target Price Lowered | BMRN Stock News - GuruFocus
- 4 weeks ago - BioMarin (BMRN) Achieves FDA Priority Review for Expanded Use of Palynziq - GuruFocus
- 4 weeks ago - FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria - PRNewsWire
- 4 weeks ago - Beyond the Balance Sheet: What SWOT Reveals About BioMarin Pharmaceutical Inc (BMRN) - GuruFocus
- 4 weeks ago - Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday - The Motley Fool